- Product Partners
- Supplements Facts
- Scientific References
- Client Reviews
The “Active” Form of CoQ10 That Your Body Uses…
Traditional CoQ10 supplements are made using the oxidized form of CoQ10 known as ubiquinone. Once absorbed, ubiquinone needs to be converted by the body to ubiquinol, the active form of CoQ10.
About 90% of the CoQ10 used by the body is the ubiquinol form. However, the ubiquinone to ubiquinol conversion process involves 17 different steps - and gets progressively more difficult for your body to do efficiently once you’re past the age of 20.
Until recently, ubiquinol wasn’t available for use in supplements because it is easily oxidized (causing it to revert to ubiquinone). That changed with the introduction of a stabilized ubiquinol called Kaneka QH™ - which is used in TrueCoQ10™.
Kaneka QH™ ubiquinol has been shown to be up to eight times more effective than ubiquinone at raising blood levels of CoQ10.
TrueCoQ10™ is also made with the CoQH-CF™ technology which helps in both the absorption and stabilization of the Kaneka QH™ ubiquinol.
CoQ10 used in supplements tends to crystalize at normal temperatures. These crystals make it very difficult for your body to absorb CoQ10. CoQH-CF™ eliminates this concern and keeps the ubiquinol fully solubilized - allowing TrueCoQ10 to be readily and quickly absorbed.
A clinical study that combined CoQH-CF™ and 100mg of Kaneka QH™ ubiquinol found that it raised blood CoQ10 levels 430% better than regular CoQ10.
As important, CoQH-CF™ uses alpha lipoic acid and other nutritional compounds to make sure Kaneka QH™ ubiquinol stays as ubiquinol in the bottle, and doesn’t oxidize.
Together, Kaneka QH™ ubiquinol and CoQH-CF™ help maximize the benefits of supplementing with TrueCoQ10™.
Kaneka QH™ and CoQH-CF™: The Ultimate “Active” CoQ10 Supplement in TrueCoQ10™
CoQ10 in the form of ubiquinol is preferred to ubiquinone for these three reasons:
1. Ubiquinol is easier for your body to absorb than ubiquinone because it naturally binds to water more easily.
2. Ubiquinol is the “reduced” or antioxidant ready form of CoQ10. This means that it can instantly stabilize a free radical - and stop its destructive path. On the other hand, ubiquinone is already “oxidized” and needs to be converted back to an antioxidant before it can help.
3. Higher amounts of ubiquinol have been linked to better health and slower aging of the body. It’s not just the total amount of CoQ10 in your body that’s important - it’s a higher amount of ubiquinol relative to ubiquinone that is critical.
As you may know, until fairly recently ubiquinol wasn’t available for use in supplements because it’s extremely difficult to keep stable and oxidizes very easily.
But thanks to the efforts of the leading maker of CoQ10, Kaneka Corporation of Japan, this challenge has been overcome. Kaneka QH™ is the world’s first and only ubiquinol available as a supplement.
Kaneka QH™ ubiquinol is made using an all-natural yeast fermentation process. It has been shown to be significantly more absorbable that conventional CoQ10, which means optimal levels of CoQ10 can be restored quickly and efficiently.
In general, to bring your CoQ10 levels to an optimal range, Dr. Robert Barry, Head of Scientific Affairs at Kaneka, recommends you take 200mg of ubiquinol for two weeks and thereafter 100mg is typically a good maintenance dose.
Without a doubt, Kaneka did an incredible job figuring out how to stabilize the fickle ubiquinol molecule.
But what matters to you is that it’s still ubiquinol when you take it. Kaneka is just the beginning of the process.
What happens between the time Kaneka makes the ubiquinol and it gets made into a supplement and delivered to you is equally important.
As you now know, extreme care is needed to protect ubiquinol from being oxidized - else it turns into the less potent ubiquinone.
And TrueCoQ10™ is made with a patent pending technology designed specifically to prevent Kaneka QH™ from oxidizing while in the bottle.
This patent pending system, called CoQH-CF™, was created by Soft Gel Technologies, Inc.® - a company dedicated to making premium quality soft gel products.
And each soft gel in your bottle of TrueCoQ10™ contains their proprietary formula which is as follows:
This patent pending combination has been shown to prevent ubiquinol from oxidizing for the entire two year shelf life of a bottle of TrueCoQ10™.
It’s important for you to know that this isn’t the case with all ubiquinol products you see for sale.
In fact, Soft Gel Technologies® has found that in other products - not made by them-- the ubiquinol frequently oxidizes and converts to ubiquinone in less than one year.
Imagine how disappointed you would be if you were looking forward to all of the incredible benefits of the ubiquinol - but the product oxidized while still in the bottle. You do not have to worry about that with TrueCoQ10™ - you can use it with complete confidence.
Still better, there is another important benefit you get from the unique way TrueCoQ10™ is made -it keeps the ubiquinol from “crystallizing.”
This is important because when CoQ10 - either ubiquinol or ubiquinone - sits in liquid solution, it wants to crystallize into solid molecules.
You can’t see this with the naked eye, but it is clearly visible under a microscope. And when CoQ10 crystallizes or solidifies, it becomes extremely difficult for your body to absorb.
The bottom line? You absorb TrueCoQ10™ much better. And this was shown in the recent clinical study published in the Journal of Functional Foods that found 430% better potency and faster absorption.
Together, Kaneka QH™ and CoQH-CF™ make TrueCoQ10™ the ultimate ubiquinol supplement!
Dietary Supplement / 30 Softgels
Serving Size: 1 Softgel
Servings per Container: 30
|Amount Per Serving||% Daily Value|
|Calories from Fat||0 g|
|Total Fat||0 g||0%*|
|CoQH-CF™ ubiquinol (Kaneka QH Ubiquinol™ reduced form of CoQ10)||50mg||**|
* Percent Daily Values are based on a 2000 calorie diet
** Daily value not established
Other ingredients: D-limonene oil, gelatin, glycerin, purified water, caprylic acid, capric acid, caramel liquid, alpha lipoic acid
Kaneka QH™ is a trademark of Kaneka Corporation.
CoQH-CF™ is a trademark of Soft Gel Technologies, Inc.
TrueCoQ10™ contains the most advanced form of CoQ10 called "ubiquinol". It has been shown to be up to eight times more efficient at raising CoQ10 blood levels than the more common "ubiquinone" form of CoQ10†. The ubiquinol is combined with special "crystal-free" technology to create CoQH-CF™
- which provides superior CoQ10 benefits.
TrueCoQ10™ promotes heart and brain health, increased energy and helps protect against free radical damage.†
Suggested Use: Take one (1) to two (2) soft gels daily with meals.
Keep out of reach of children.
Store at 15-30° C (59-86° F).
Protect from heat, light and moisture.
Do not purchase if seal is broken.
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
- Assembled in the USA
Manufactured for and Distributed by: NatureCity®
Boca Raton, FL 33487 www.naturecity.com
To re-order call toll free 1-800-593-2563
Taylor BA, Lorson L, White CM, Thompson PD. “A randomized trial of coenzyme Q10 in patients with confirmed Statin Myopathy” Atherosclerosis. 2015 Feb;238(2):329-35.
Bates A, Shen Q, Hiebert JB, Thimmesch A, Pierce JD. “Myocardial energetics and ubiquinol in diastolic heart failure.” Nurs Health Sci. 2014 Dec;16(4):428-33
Kizaki K, Terada T, Arikawa H, Tajima T, Imai H, Takahashi T, Era S. “Effect of reduced coenzyme Q10 (ubiquinol) supplementation on blood pressure and muscle damage during kendo training camp: a double-blind, randomized controlled study.” J Sports Med Phys Fitness. 2014 Nov 4
Gvozdjáková A, Kucharská J, Ostatníková D, Babinská K, Nakládal D, Crane FL. “Ubiquinol improves symptoms in children with autism.” Oxidative Medicine and Cellular Longevity, 2014;2014:798957.
Onur S, Niklowitz P, Jacobs G, Nöthlings U, Lieb W, Menke T, Döring F. “Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans.” BMC Res Notes. 2014 Jul 4;7:427.
Cakiroglu B, Eyyupoglu SE, Gozukucuk R, Uyanik BS. “Ubiquinol effect on sperm parameters in subfertile men who have astheno-teratozoospermia with normal sperm concentration.” Nephrourol Mon. 2014 May 10;6(3):e16870.
Failla ML, Chitchumroonchokchai C, Aoki F. “ Increased bioavailability of ubiquinol compared to that of ubiquinone is due to more efficient micellarization during digestion and greater GSH-dependent uptake and basolateral secretion by Caco-2 cells.” J Agric Food Chem. 2014 Jul 23;62(29):7174-82.
García-Corzo L, Luna-Sánchez M, Doerrier C, Ortiz F, Escames G, Acuña-Castroviejo D, López LC. “Ubiquinol-10 ameliorates mitochondrial encephalopathy associated with CoQ deficiency.” Biochim Biophys Acta. 2014 Jul;1842(7):893-901.
Alf D, Schmidt ME, Siebrecht SC. “Ubiquinol supplementation enhances peak power production in trained athletes: a double-blind, placebo controlled study.” J Int Soc Sports Nutr. 2013 Apr 29;10:24.
Miyamae T, Seki M, Naga T, Uchino S, Asazuma H, Yoshida T, Iizuka Y, Kikuchi M, Imagawa T, Natsumeda Y, Yokota S, Yamamoto Y. “Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation.” Redox Rep. 2013;18(1):12-9.
Fischer A, Onur S, Schmelzer C, Döring F. “Ubiquinol decreases monocytic expression and DNA methylation of the pro-inflammatory chemokine ligand 2 gene in humans.” BMC Res Notes. 2012 Oct 1;5:540.
Mezawa M, Takemoto M, Onishi S, Ishibashi R, Ishikawa T, Yamaga M, Fujimoto M, Okabe E, He P, Kobayashi K, Yokote K. “The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study.” Biofactors, 2012 Nov-Dec;38(6):416-21.
Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. “Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study”. J Urol. 2012 Aug;188(2):526-31.
Schmelzer C, Niklowitz P, Okun JG, Haas D, Menke T, Döring F. Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans. IUBMB Life. 2011 January 63(1):42-8.
Malkanthi Evans, Joshua Baisley, Sonya Barss, Najla Guthrie “A randomized, double-blind trial on the bioavailability of two CoQ10 formulations” Journal of Functional Foods I (2009) 65-73.
Langsjoen PH, Langsjoen AM. “Supplemental ubiquinol in patients with advanced congestive heart failure.” Biofactors. 2008;32(1-4):119-28.
Hosoe K, Kitano M, Kishida H, Kubo H, Fujii K, Kitahara M. “Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers.” Regul Toxicol Pharmacol. 2007 Feb;47(1):19-28.
Yan J, Fujii K, Yao J, et al. Reduced coenzyme Q10 supplementation decelerates senescence in SAMP1 mice. Exp Gerontol. 2006 Feb;41(2):130-40.
Seet RC, Lim EC, Tan JJ, Quek AM, Chow AW, Chong WL, Ng MP, Ong CN, Halliwell B. “Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson's disease?” Antioxid Redox Signal. 2014 Jul 10;21(2):211-7.
Fotino A, Thompson-Paul A, Bazzano L. “Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis.” The American Journal of Clinical Nutrition, February 2013 97: 268-275.
Hernández-Ojeda J, Cardona-Muñoz EG, Román-Pintos LM, Troyo-Sanromán R, Ortiz-Lazareno PC, Cárdenas-Meza MA, Pascoe-González S, Miranda-Díaz AG “The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study.” J Diabetes Complications. 2012 Jul-Aug;26(4):352-8.
Gao L, Mao Q, Cao J, Wang Y, Zhou X, Fan L. “Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials.” Atherosclerosis, 2012 Apr;221(2):311-6.
Lee BJ, Huang YC, Chen SJ, Lin PT. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition. 2012 Jul;28(7-8):767-72.
Alehagen U, Johansson P, Bjornstedt M, Rosen A, Dahlstrom U. “Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens.” Int J Cardiol. 2012 May 22.
Gökbel H, Gül I, Belviranl M, Okudan N. “The effects of coenzyme Q10 supplementation on performance during repeated bouts of supramaximal exercise in sedentary men.” The Journal of Strength & Conditioning Research, 2010 Jan;24(1):97-102.
Hamilton SJ, Chew GT, Watts GF. “Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients.” Diabetes Care, 2009 May;32(5):810-2.
Cooke M, Iosia M, Buford T, Shelmadine B, Hudson G, Kerksick C, Rasmussen C, Greenwood M, Leutholtz B, Willoughby D, Kreider R. “Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals.” Journal of the International Society of Sports Nutrition, 2008 Mar 4;5:8.
Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, Richards AM. “Coenzyme Q10: an independent predictor of mortality in chronic heart failure.” Journal of the American College of Cardiology. 2008 Oct 28;52(18):1435-41.
Kon M, Tanabe K, Akimoto T, Kimura F, Tanimura Y, Shimizu K, Okamoto T, Kono I. “Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10.” British Journal of Nutrition, 2008 Oct;100(4):903-9.
Zheng A1, Moritani T. “Influence of CoQ10 on autonomic nervous activity and energy metabolism during exercise in healthy subjects.” Journal of nutritional science and vitaminology, 2008 Aug;54(4):286-90.
Rosenfeldt F, Haas S, Krum H, Hadj A, Ng K, Leong J, Watts G. “Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials.” Journal of Human Hypertension, 2007 21, 297–306.
Tiano L, Belardinelli R, Carnevali P, Principi F, Seddaiu G, Littarru GP. “Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study.” European Heart Journal, 2007 Sep;28(18):2249-55.
Rosenfeldt F, Marasco S, Lyon W, Wowk M, Sheeran F, Bailey M, Esmore D, Davis B, Pick A, Rabinov M, Smith J, Nagley P, Pepe S. “Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue.” The Journal of Thoracic and Cardiovascular Surgery, 2005 Jan;129(1):25-32.
Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J. “Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.” Neuorology, 2005 Feb 22;64(4):713-5.
Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. “Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus.” Diabetologia, 2002 Mar;45(3):420-6.
Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. “Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.” European Journal of Clinical Nutrition, 2002 Nov;56(11):1137-42.
Shults CW, Oakes D, Kieburtz K, et al. “Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.” Archives of Neurology, 2002 Oct;59(10):1541-50.
Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD. “Open label trial of coenzyme Q10 as a migraine preventive.” Cephalalgia. 2002 Mar;22(2):137-41.
Singh RB, Wander GS, Rastogi A, Shukla PK, Mittal A, Sharma JP, Mehrotra SK, Kapoor R, Chopra RK. “Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction.” Cardiovascular Drugs and Therapy, 1998 Sep;12(4):347-53.
Lewin A, Lavon H. “The effect of coenzyme Q10 on sperm motility and function.” Molecular Aspects of Medicine, 1997;18 Suppl:S213-9.
Langsjoen PH, Vadhanavikit S, Folkers K. “Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10.” Proceedings of the National Academy of Sciences of the United States of America. 1985 Jun;82(12):4240-4.